A new study reveals that PET/MR imaging is highly effective in detecting coronary artery disease, outperforming traditional SPECT methods. The hybrid technique provides a comprehensive view of the heart, combining anatomical and functional information for more accurate diagnoses.
Researchers can conduct five different imaging studies in one scan with the Opti-SPECT/PET/CT system, providing comprehensive data on anatomy and physiological processes. The device allows for minimally invasive studies with a single dose of anesthesia, enabling scientists to develop new drug discovery methods.
A comprehensive clinical trial found that SPECT/CT imaging detected significantly more sentinel lymph node involvement with various types of cancers, including melanoma, breast carcinoma, and pelvic malignancies. This improved imaging technique has the potential to alter surgical planning and improve patient outcomes.
Researchers used a novel radioluminescence microscope to study single cells and found unexpected variation. The tool helps personalize radionuclide imaging by characterizing how radiotracers interact with cells.
A new study shows that administering G-CSF, a stem cell-stimulating therapy, early in the treatment of heart attack patients can improve their chances of survival and cardiac function. The therapy was found to increase blood flow, access to energy, and overall cardiac health.
A novel F-18 labeled tracer, F-18 THK5117, selectively binds to tau/neurofibrillary tangles in Alzheimer's brains. This study demonstrates the potential for F-18 THK5117 to develop new anti-dementia drugs.
Researchers link late-life depression to accelerated Alzheimer's disease development through beta-amyloid accumulation. Mild cognitive impairment patients with depressive symptoms showed higher amyloid deposition than non-depressed controls.
Siegel's work on PET has led to a major advance in nuclear medicine science, with a focus on evidence-based clinical trials and widespread acceptance of imaging studies. He is recognized for his visionary leadership in developing scientific methodology.
Researchers used SPECT and PET systems to detect inflammation involved in osteoarthritis, giving doctors a clear read on chronic pain and possible joint destruction. Radiolabeled anti-FAP antibodies showed significantly increased imaging agent uptake in inflamed joints.
A new molecular breast imaging protocol using a higher dose of Tc-99m filtered sulfur colloid has been shown to improve the detection of advanced breast cancer. Imaging performed the day prior to surgery was more sensitive than imaging on the day of surgery, detecting 76% versus 49% of cases with metastasized lymph nodes.
Researchers have developed a novel imaging agent, Tc-99m MIP-1404, which binds to PSMA enzyme in prostate cancer cells, enabling detection of metastases. The agent shows promise in detecting lesions more accurately than standard bone imaging.
Researchers developed a new dual agent scan that can differentiate between diabetic foot infection and a non-infectious complication in nerve-damaged joints. The technique combines agents targeting bone cell activity and immune response, allowing doctors to accurately diagnose and rule out unnecessary scans.
The new SPECT/MR system offers exceptional molecular imaging capabilities, reducing patient exposure to ionizing radiation and offering customized multifunctional imaging. It has the potential to diversify options for clinicians and biomedical investigators, with possible human trials in the near future.
A new method of dose calculation estimates radiation absorbed dose in radioimmunotherapy, predicting progression-free survival and enabling personalized treatment. Patients receiving higher doses (>200 centigray) had significantly longer progression-free survival.
Researchers at RIKEN have developed a new molecular imaging technology that visualizes both bio-metals and molecules simultaneously in a live mouse. This breakthrough technology is expected to provide insights into the complex interactions between metal elements and associated bio-molecules in diseases such as diabetes and cancer.
Two novel radiolabeled small molecules targeting PSMA have excellent potential for diagnosing and staging prostate cancer. The imaging agents showed a high sensitivity of lesion detection in bone, soft tissue, and the prostate gland.
Researchers found that the lateral and orbital regions of the frontal cortex interact during drug-related cues, suggesting that addiction may result from abnormal brain circuitry. The study's findings suggest that a therapeutic approach for addiction could be developed by targeting this neural circuit.
Researchers have achieved two significant 'firsts' in studying the human cardiac protein alpha-tropomyosin, which controls heart contraction on every beat. By direct imaging, they found individual molecules to be roughly 40 nanometers long and demonstrated their flexibility, establishing a baseline for normal protein function.
A new molecular imaging method using PET/CT with Gallium-68 DOTATATE identifies hormonally active tissues, allowing clinicians to re-evaluate patient management. This technique changes treatment plans in over 35% of patients, saving them from unnecessary surgeries.
Research finds that combining molecular imaging with computed tomography (CT) can reduce patient radiation dose. By using just one CT scan for multiple PET studies, researchers lower radiation exposure and improve image quality.
Researchers develop a molecular imaging tool to detect coronary artery disease, which is caused by atherosclerosis. The technique measures the coronary flow reserve, or CFR, and calculates precise dilation of blood vessels at rest and under stress.
Piramal Imaging will present data from five florbetaben studies, including a pivotal Phase III trial that will provide the basis for regulatory submission later this year. The company is developing an innovative and proprietary tracer portfolio to address major clinical needs in Alzheimer's disease and other conditions.
Researchers at Berkeley Lab have provided the first experimental determination of the pathways by which electrical charge is transported in organic thin films. By chemically modifying these films, they show improved conductance and pave the way for future organic electronic devices with better performance.
A new review of imaging studies confirms that positron emission tomography (PET) safely and accurately detects dementia, including the most common form among the elderly, Alzheimer's disease. The study found that combining PET with a biomarker called 18F-FDG can pinpoint key areas of metabolic decline in the brain indicating dementia.
A new PET technique using FLT-PET has shown highly sensitive imaging for patients with mantle cell lymphoma, a relatively rare and devastating blood cancer. The study found that all cancerous lesions were very highly visible using FLT-PET, providing a powerful biomarker for MCL.
Researchers found that responders with high exposure to the dust cloud had high-risk features of atherosclerosis and impaired vascular reactivity. The study used MRI imaging to evaluate cardiovascular risk in WTC first responders.
Researchers at Purdue University have developed a new imaging technology that uses nanosecond laser pulses to measure ultrasound signals from molecules, enabling precise three-dimensional images of arterial plaques. This breakthrough could lead to better diagnoses and treatments for cardiovascular disease and other disorders.
Researchers combined two molecular imaging agents to create a powerful new tool for acquiring information about the extent of a patient's cancer. The results showed that combined 18F NaF and 18F FDG PET/CT imaging provided good-quality imaging of both skeletal and extra-skeletal malignant lesions from various cancers.
Researchers have successfully used oatmeal products radiolabeled with a medical isotope to image stomach emptying in molecular imaging studies. The study demonstrated that prior boiling and labeling of oatmeal improves radiolabeling efficiency, making it an effective alternative to egg meal for patients with dietary restrictions.
Researchers developed a molecular imaging technique that can detect reduced blood flow in diabetic hearts, potentially saving lives. The study found that this method is safe and beneficial for predicting cardiac events in diabetic patients suspected of having ischemic heart disease.
A molecular imaging procedure using PET/CT and F18 NaF radiotracer accurately diagnoses and manages chronic back pain by pinpointing the source of abnormal bone reaction. In a study, this method was found to be highly effective in more than 85% of cases, providing relief for patients with hardware implants or bone grafts.
Researchers use molecular imaging to gauge heart efficiency in subjects with a pathogenic mutation linked to HCM. They find carriers of the mutation already have less efficient hearts despite the absence of any symptoms. Alcohol septal ablation is shown to be an effective treatment for symptomatic patients who remain symptomatic despit...
A study published at SNM's 58th Annual Meeting found that molecular imaging, specifically FDG-PET scans, can effectively diagnose the cause of fever of unknown origin. The research suggests that FDG-PET may improve patients' prognosis and cut healthcare costs by providing a non-invasive diagnostic tool.
Researchers found significant improvements in lesion detection with whole-body TOF FDG PET scans, particularly in larger patients and shorter studies. TOF scans yielded better image signal-to-noise due to travel time consideration, reducing scanning time and patient motion.
A new study uses PET scans to image metabolic changes in thyroid cancer patients treated with vandetanib, a protein kinase inhibitor. The findings show that PET imaging can help define the therapy response and identify potential markers of treatment efficacy.
A new molecular imaging technology has been developed by researchers at Universidad Carlos III de Madrid to detect live cellular processes. This technology differs from conventional medical imaging, allowing for earlier detection of anomalies and facilitating treatment.
A study found that PET/CT scans can predict local recurrence in lung cancer patients treated with radiofrequency ablation by analyzing lesion size, tumor type, and glucose metabolic activity. This non-invasive tool may help improve diagnosis and treatment of lung cancer.
The Euro-BioImaging project will develop a comprehensive plan to construct and operate a set of complementary imaging infrastructure facilities across Europe. This will enable scientists to access state-of-the-art imaging technologies, receive training, and facilitate the translation of basic results to medical applications.
Researchers have developed a new imaging technology that combines photoacoustic tomography with gold nanobeacons, allowing for unprecedented detail in visualizing blood vessel formation. This breakthrough has the potential to help healthcare providers diagnose diseases earlier and more accurately.
A new study using positron emission tomography (PET) and magnetic resonance imaging (MRI) found that traumatic brain injuries lead to widespread decreases in brain functioning, particularly in the hippocampus. The research suggests a time window during which intervention could mitigate long-term neurological consequences.
A molecular imaging technique may help identify early response to treatment in cisplatin-resistant ovarian cancer, potentially reducing unnecessary side effects and offering more effective treatments. Researchers used a PET probe to monitor tumor growth in mice with human ovarian cancer.
Studies show molecular imaging improves evaluation and treatment planning for various cancers, including thyroid cancer, lymphoma, and non-small cell lung cancer. The technique allows doctors to identify disease severity and extent, providing personalized care and adjusting treatment plans accordingly.
A new imaging method can identify high-risk patients with potentially life-threatening cardiovascular conditions, helping physicians determine which patients are best suited for implantable cardioverter defibrillator therapy. This technique also helps avoid overuse or underuse of ICD treatment.
Researchers developed a novel optical imaging technique called Cerenkov Luminescence Imaging (CLI) that could lead to faster development of radiopharmaceuticals. CLI harnesses the speed of light to visualize medical isotopes, overcoming current limitations in nuclear imaging modalities.
The meeting showcased groundbreaking research and development worldwide in molecular imaging and nuclear medicine, with a focus on using molecular imaging to understand disease mechanisms and improve patient health. Key findings included advances in Alzheimer's disease identification and recurrent prostate cancer detection.
Chester A. Mathis receives SNM's 2010 Aebersold Award for his groundbreaking work on early detection in Alzheimer's disease using positron emission tomography (PET) imaging techniques. This recognition acknowledges the significant contributions of Dr. Mathis to advancing molecular imaging and nuclear medicine.
Bengt Roland Långström, a professor at Uppsala University in Sweden, has been recognized for his work in nuclear medicine. He is being honored with the Georg Charles de Hevesy Nuclear Pioneer Award for his over 20 years of experience in synthesizing and applying radiolabeled tracers for PET.
Researchers developed a non-invasive imaging technique combining PET and CT scans without bowel preparation, detecting all significant polyps found by colonoscopy. Patients preferred this method over colonoscopy due to its comfort and lack of sedation.
The Journal of Nuclear Medicine published a supplement on cardiovascular molecular imaging, discussing its potential to diagnose heart diseases earlier. The publication combines various imaging techniques, such as ultrasound, MRI, and radiotracers, to improve management of cardiovascular disease.
Research published in The Journal of Nuclear Medicine suggests that molecular imaging using 18F-FDG PET/CT can help diagnose acute and chronic aortic dissection. This non-invasive technique can provide images to determine the difference between acute and chronic dissections, helping doctors decide the best course of treatment.
The Society of Nuclear Medicine and Molecular Imaging (SNM) has received a $48,000 grant from the Agency for Healthcare Research and Quality (AHRQ) to develop research on comparative effectiveness of PET and other molecular imaging techniques. The primary emphasis will be on cancer diagnosis and management, with cardiology and neurolog...
A new imaging technique using FDG PET can help doctors plan cardiac procedures, reducing cost and improving patient outcomes. The study found a trend toward better patient outcomes when FDG PET is used in diagnostic work-up.
Researchers develop fluoromodules, dye-protein complexes that provide alternatives to GFP with a wider selection of colors and increased photostability. This technology enables real-time monitoring of biological activities in living cells.
SNM's Clinical Trials Network has gained a new member, Eli Lilly and Company, which will support the initiative to facilitate the development of therapeutic medicines. The network aims to streamline drug discovery and integrate imaging biomarkers into clinical trials, ultimately leading to personalized diagnostics and therapies.
Springer has partnered with the Korean Society of Nuclear Medicine (KSNM) to publish the journal Nuclear Medicine and Molecular Imaging. The journal will be available in both print and electronic formats, providing a platform for high-quality research and discussion on nuclear medicine and related sciences.
A new imaging technique combines ultrasound and specially modified contrast agents to detect cancer at the molecular level, allowing for early detection and potentially saving lives. The technique uses microbubbles paired with a peptide that binds to tumor vessel cells, enabling visualization of tumor activity.
The Society of Nuclear Medicine and Molecular Imaging's Clinical Trials Network Workshop explored the integration of imaging biomarkers into clinical trials, emphasizing quality and standardization. Experts shared insights on overcoming challenges and harmonizing data across multiple sites.
The summit explored ways to use nanotechnology in medical imaging and therapy, focusing on targeting diseases such as cancer, neurological conditions, and cardiovascular disease. Experts discussed regulatory frameworks, design considerations, and future directions for this rapidly evolving field.
A new study provides clear pediatric PET dose guidelines, allowing clinicians to calculate the optimal radiotracer dose based on a child's weight. The findings suggest that patients can receive high-quality images with reduced scan time or lower doses, minimizing radiation exposure for young children.
Researchers at Lawrence Berkeley National Laboratory have developed a copper-free version of click chemistry to label glycans in live mice, providing new insights into glycobiology and molecular imaging. The technique overcomes the toxicity issue of conventional copper-catalyzed reactions.